Comparative Pharmacology
Head-to-head clinical analysis: PLEGINE versus SANOREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLEGINE versus SANOREX.
PLEGINE vs SANOREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Plegine (phendimetrazine) is a sympathomimetic amine that acts as an anorectic agent. It stimulates the hypothalamus to release norepinephrine and dopamine, thereby suppressing appetite. The exact mechanism is thought to involve the release of catecholamines from presynaptic nerve terminals in the lateral hypothalamic feeding center, leading to decreased food intake.
Serotonin 5-HT2C receptor agonist; stimulates pro-opiomelanocortin (POMC) neurons, leading to release of α-melanocyte-stimulating hormone (α-MSH) and activation of melanocortin-4 receptors in the hypothalamus, reducing appetite.
25-50 mg orally once daily at bedtime, maximum 100 mg/day.
Oral: 1 mg twice daily for 12 weeks; maximum dose: 2 mg/day.
None Documented
None Documented
Terminal elimination half-life: 4–8 hours (mean 6 hours). Clinical context: Steady-state achieved after 24–48 hours of repeated dosing.
Terminal elimination half-life: 2-4 hours; context: requires multiple daily dosing to maintain therapeutic effect.
Renal: 40% unchanged; Hepatic metabolism: 60% (biliary/fecal elimination of metabolites).
Renal: 90% unchanged; biliary/fecal: 10%
Category C
Category C
Anorexiant
Anorexiant